Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
- Effect of Delayed Release Metformin on Plasma Glucose Level
- Leisure Exercise Reduces Heart Disease by 25% for Younger Women
- GLP-1 Receptor Agonist vs Insulin: Mortality Rate and Cardiovascular Risk
- Exclusive Interview Transcript: Robert H. Eckel, M.D.
- Guest article: David Kliff, Diabetic Investor
Letter from the Editor
Last week the FDA announced that they were going to approve 6 different manufacturers for the production of rosuvastatin calcium, the generic version of Crestor. It appears that the FDA has decided that if they let more companies produce the generic, the price may not be as high to start with. This is a good signal for patients that have been successful with Crestor in the past. However, for those patients who have not responded well to rosuvastatin or any of the other statins, there is a whole new class of drugs that prescribers now have available.
This class, known as the PCSK9 Inhibitors, holds a lot of promise for many patients who have been unsuccessful at lowering their LDLs.
This week, we have an interview that Steve Freed, our publisher, did with Dr. Robert Eckel, the Charles A. Boettcher Endowed Chair in Atherosclerosis, Professor of Medicine – Division of Endocrinology, Metabolism and Diabetes, and Cardiology, University of Colorado, Anschutz Medical Campus, at the recent AACE Meeting.
Dr. Eckel — who has type 1 diabetes — discusses the complexity of treating diabetes, and how the use of these new PCSK9 inhibitors affects LDL and diabetes.
*****************************
We can make a difference!
*****************************
Dave Joffe, Editor-in-chief
This Week's Survey
Since the result of this Presidential election will have a major impact on our nation’s healthcare, which candidate are you leaning towards? Follow the link to share your opinion!
Patient App
BlueLoop is a tool for children with diabetes. It provides care coordination among caregivers, improving a child’s and family’s ability to manage diabetes, especially when the child is away from home.
Test Your Knowledge
Less-stringent A1C goals (7.5 – 8.0%) may be acceptable in certain individuals with type 2 diabetes. Which factor(s) support less stringent goals?
A) Limited life expectancy
B) History of severe hypoglycemia
C) Multiple comorbidities
D) All of the above
Did you get it right? Follow the link to find out!
Did You Know: Ride a Bike to Lower Diabetes Risk by At Least 20%
A two-wheel ride instead of four could help lower the risk of developing type 2 diabetes among adults, a new study in Denmark revealed.
People who rode a bike to work or cycled just for fun were less likely to get the diabetes, researchers found. This was true even for those who only began habitual cycling later in life. According to a recent study, people who bike ride regularly—for pleasure or as a means of transportation—have a reduced risk of developing type 2 diabetes.
After 5 years, the biking habits of study participants were re-evaluated, and at that time, those who had begun riding regularly experienced a 20% lower diabetes risk than those who did not cycle. Researchers acknowledge the study revealed an association between bicycle riding and reduced risk for type 2 diabetes—but not a cause-effect relationship.
Interestingly, people who started bicycling later in life also had a decreased risk for diabetes. Bike riding has a number of health benefits, and now it seems, maintaining healthy blood sugar levels can be added to the list.
Details of the study were published in the journal PLOS Medicine. Rasmussen MG, Grøntved A, Blond K, Overvad K, Tjønneland A, Jensen MK, et al. Associations between recreational and commuter cycling, changes in cycling, and type 2 diabetes risk: a cohort study of Danish men and women. PLoS Med. 2016;13:e1002076. View Article
Coming Soon: An article on a personal experience using an e-Bike built to lower blood sugars!
Is once-daily delayed release metformin better than the other forms of metformin?
We have studies that show exercise for older women is very beneficial; new study shows benefits for the young.
Does insulin cause more deaths and cardiovascular outcomes than GLP-1 agonist receptors?
Exclusive Interview with Dr. Robert H. Eckel
In Part 1 of this exclusive interview, Dr. Eckel discusses the new PCSK9 inhibitors, treating complicated patients, and the challenges of type 2.
In part 2 of this exclusive interview, Dr. Eckel discusses the new diabetes drugs that offer treatment benefits beyond glucose control, and why 1 + 1 + 1 + 1 may add up to more than 4 when impacting multiple risks.
In part 3 of this exclusive interview, Dr. Eckel discusses the new PCSK9 Inhibitors and their LDL-lowering effects, and why they are beneficial for statin-intolerant patients.
Guest Article by David Kliff
Recently Beta Bionics, the makers of the iLet artificial pancreas, reached a significant milestone: raising $1 million through online public fundraising. It is no longer a question of if an artificial pancreas will exist, but of when it will become commercially available. With every major insulin pump company working in this area, along with many startups, patients will not just have one system, but several they can chose from.
Quote of the Week!
“It is never too late to be what you might have been.”
…George Eliot
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com